HLS-Rugged point-of-care device for global hemostasis testing of whole blood

HLS-Rugged 现场护理设备，用于全血的全球止血测试

• 批准号: 9241591
• 负责人: Richard Chasen Spero
• 金额: $ 108.94万
• 依托单位: REDBUD LABS, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9241591
• 关键词: Accident and Emergency department; Animal Model; Area; Blood; Blood Coagulation Disorders; Caring; Childhood; Clinical; Clinical Research; Clinical Trials; Coagulation Process; Correlation Studies; Cytolysis; Data; Device or Instrument Development; Devices; Diagnosis; Diagnostic; Emergency Medicine; Environment; Functional disorder; Goals; Gold; Health; Hemostatic function; Hospitals; Human; Kinetics; Letters; Magnetism; Marketing; Measurement; Measures; Medical Device; Microfluidics; Morbidity - disease rate; Neonatal; Optics; Patients; Performance; Phase; Publishing; Regulatory Affairs; Research; Role; Sampling; Small Business Innovation Research Grant; Surface; System; Technology; Testing; Time; Trauma; Validation; Whole Blood; base; blood product; commercialization; cost; diagnosis standard; healthy volunteer; improved; in vitro Model; industry partner; meetings; mortality; nano; point of care; pre-clinical; quality assurance

DESCRIPTION (provided by applicant): Rheomics is developing a global hemostasis test that uses whole blood. It will enable faster diagnosis and goal-directed therapy of coagulopathies associated with trauma. It will reduce morbidity, mortality, and costs associated with blood product therapy. Our device measures clotting time, kinetics, stiffness, and lysis. Unlike existing devices, ours will use an inexpensive, disposable microfluidic test strip and a robust, easy-to-use analyzer. Our goal is to improve care for the many patients-as many as 6.2 million, just in the US-who develop a coagulation dysfunction that triples their chance of dying. At the same time, we can save hundreds of dollars per patient and hundreds of thousands of dollars for hospital systems.

描述（由申请人提供）：Rheomics正在开发一种使用全血的全球止血测试。它将能够更快地诊断和目标导向治疗与创伤有关的凝血功能障碍。它将降低与血液制品治疗相关的发病率、死亡率和成本。我们的设备测量凝血时间、动力学、硬度和溶解。不同于现有 我们将使用廉价的一次性微流控测试条和耐用的易于使用的分析仪。我们的目标是改善对许多患者的护理--仅在美国就有620万人--他们患上了凝血功能障碍，死亡率是原来的三倍。与此同时，我们可以为每位患者节省数百美元，为医院系统节省数十万美元。